News

The transaction values the US-based biotechnology company at approximately $3bn post-money. Bristol Myers Squibb (BMS) led the funding round, with further capital provided by existing investors. Pathos AI

The partnership focuses on evaluating digital patient twins, which are computer-based models of individual patients constructed from clinical and related data. The companies intend to examine whether these

The financial package includes an upfront payment alongside milestone payments tied to specific development, regulatory, and commercial targets. Royalties on net sales remain separate from the package. Kaigene

Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at targets selected

The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. Applicable to patients irrespective of cisplatin eligibility,

The regulatory decision represents the first new drug application (NDA) approval secured by the speciality pharmaceutical manufacturer. Cosette expects the therapy to be commercially accessible in the US

Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio’s TERA technology. The partnership divides research and clinical duties between

In the US, Ryzumvi is already marketed as the sole authorised treatment for pharmacologically-induced mydriasis. Under a global licensing agreement with Opus Genetics, Viatris holds exclusive rights to

The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direct kidney delivery. The total